In this study, compared with P2S peptide–treated A549 cells, the levels of mesenchymal markers integrin β1, N-cadherin, and fibronectin were lower in the MF of P2 peptide–treated A549 cancer cells (Fig. 3F; Appendix Fig. S1H). The gene discussed is CDH2; the disease is cancer.